Figures computed from official regulatory filings — .
Analysttarget 5.88 USD (+554%) · consensus 4.88/5 · 8 buy · 0 hold · 0 sell
Ownershipinsiders 29.68% · institutions 56.13% · short 6.3% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Connect Biopharma Holdings Ltd only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| LIU JEAN I | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Xanthopoulos Kleanthis Gabriel | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| LIU JEAN I | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Xanthopoulos Kleanthis Gabriel | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Huang Jamestrack record | Buy | $371.6K | conv 31 | SEC |
| Xanthopoulos Kleanthis Gabriel | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| LIU JEAN I | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Huang Jamestrack record | Buy | $4M | conv 57Unusual size | SEC |